EE531 Cost-Utility Analysis of Once-Weekly Semaglutide Versus Dulaglutide in Patients With Type 2 Diabetes Requiring Treatment With a GLP-1 Receptor Agonist
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.772
https://www.valueinhealthjournal.com/article/S1098-3015(22)02976-X/fulltext
Title :
EE531 Cost-Utility Analysis of Once-Weekly Semaglutide Versus Dulaglutide in Patients With Type 2 Diabetes Requiring Treatment With a GLP-1 Receptor Agonist
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02976-X&doi=10.1016/j.jval.2022.09.772
First page :
Section Title :
Open access? :
No
Section Order :
10316